Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors

Date

21 Oct 2023

Session

Poster session 16

Topics

Cancer Biology;  Pathology/Molecular Biology

Tumour Site

Presenters

Kristina Jansen

Citation

Annals of Oncology (2023) 34 (suppl_2): S1190-S1201. 10.1016/S0923-7534(23)01928-2

Authors

K. Jansen1, L. Kornfeld2, M. Lennartz2, N.C. Blessin2, S. Rico2, S. Kind2, V. Reiswich2, A.M. Luebke2, C. Hube-Magg2, E. Bady1, F. Büscheck2, A. Menz2, R. Uhlig2, G. Sauter2, R. Simon2, C. Bernreuther2

Author affiliations

  • 1 Institute Of Pathology, University Medical Center Hamburg-Eppendorf, 20251 - Hamburg/DE
  • 2 Institute Of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2355P

Background

Carcinoembryonic antigen (CEA; CEACAM5) is a cell surface glycoprotein which constitutes an attractive therapeutic target and serum CEA is used for cancer monitoring. CEA is overexpressed in various cancers, but the reported prevalence data vary considerably for many tumor types.

Methods

To comprehensively determine CEA expression in normal and neoplastic tissues, a tissue microarray containing 15,413 samples from 120 different tumor types and subtypes as well as 76 different normal tissue types were analyzed by immunohistochemistry.

Results

CEA positivity occurred in 65 of 120 tumor categories including 49 entities with at least one strongly positive case. CEA positivity was most common in colorectal carcinomas (98.7%), other gastrointestinal adenocarcinomas (61.1%-80.3%), medullary carcinomas of the thyroid (96.3%), pulmonary adenocarcinoma (73.7%), mucinous carcinomas of the ovary (79.8%) and the breast (43.2%), squamous cell carcinomas of various sites (30.2%-69.1%), and small cell carcinomas of the lung (64.3%), the urinary bladder (38.9%), and the prostate (50.0%). High CEA expression was linked to high grade (p<0.0001) and invasive growth (p<0.0001) in urothelial carcinoma. Reduced CEA expression was associated with mismatch repair deficiency (p<0.0001) but not with pT and pN stage in colorectal cancer.

Conclusions

In summary, CEA is abundantly expressed in a broad range of epithelial neoplasms. Our data thus identify various tumor entities where CEA positive cancers might best benefit from CEA serum monitoring and anti-CEA therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

G. Sauter: Other, Personal, Other, The CEA (MSVA-465R) antibody were provided by MS Validated Antibodies GmbH, owned by a family member of Guido Sauter, Director of the Institute: MSVA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.